UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/711,389	09/15/2004	Werner Zumbrunn	CT0002	5388
25235 HOGAN & HA	7590 07/01/200 RTSON LLP	EXAMINER		
ONE TABOR CENTER, SUITE 1500 1200 SEVENTEENTH ST			MERCIER, MELISSA S	
DENVER, CO 80202			ART UNIT	PAPER NUMBER
,			1615	
			NOTIFICATION DATE	DELIVERY MODE
			07/01/2009	ELECTRONIC

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentcolorado@hhlaw.com

	Application No.	Applicant(s)		
	10/711,389	ZUMBRUNN ET AL.		
Office Action Summary	Examiner	Art Unit		
	MELISSA S. MERCIER	1615		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
Responsive to communication(s) filed on <u>26 Not</u> This action is <b>FINAL</b> . 2b) ☑ This     Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro			
Disposition of Claims				
4) ☐ Claim(s) <u>1-37</u> is/are pending in the application. 4a) Of the above claim(s) <u>1-16,19,24,25,27-32,</u> 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) <u>17,18,20-23,26 and 33-35</u> is/are rejection of the complete com	36 and 37 is/are withdrawn from ted.	consideration.		
Application Papers				
9) The specification is objected to by the Examiner  10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the off Replacement drawing sheet(s) including the correction of the off the oath or declaration is objected to by the Example 11).	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 1-23-07, 8-17-07.	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6)  Other:	nte		

### **DETAILED ACTION**

### Election/Restrictions

Claims 1-16 and 36-37 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Groups I and III, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on August 1, 2008.

Claims 19, 24-25 and 27-32 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on November 26, 2008.

Claims 17-18, 20-23, 26 and 33-35 are under prosecution in this application.

## Information Disclosure Statement

Receipt of the Information Disclosure Statements filed on January 23, 2007 and August 17, 2007 is acknowledged. Signed copies are attached to this office action.

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 23 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 10/711,389 Page 3

Art Unit: 1615

It is unclear what the separation means "14" is meant to convey. It is suggested Applicant amend the claim to recite the actual component represented by "14".

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 17-18, 20-23, 26 and 35 are rejected under 35 U.S.C. 102(b) as being anticipated by Murdock (US Patent 6,374,136).

Murdock discloses an electrode assembly and a method of forming an anhydrous reservoirs layer of an electrode assembly in an electro transport transdermal agent delivery device. The reservoir layer is adapted to be placed in agent transmitting relation with a body surface and an electrode in electric contact with a power source and the reservoir layer. The method includes the steps of dissolving a beneficial agent in a solvent, applying the solvent and dissolved beneficial agent to a surface of a hydrophilic polymer filtration membrane, removing the solvent from the surface of the filtration membrane and disposing the beneficial agent/filtration membrane with the electrode assembly (abstract). The solvent can be removed from the polymer membrane by drying the membrane in a forced air oven, a vacuum drying oven, a desiccators, or by lyophilizing the polymer membrane (column 5, lines 48-51).

Art Unit: 1615

Applicant has identified the porous structure to be skin; therefore, application of the transdermal patch meets the limitation of arranged in the vicinity of the porous surface.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 33-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Murdock (US Patent 6,374,136) in view of Haak et al. (US Patent 5,993,435).

The teachings of Murdock are discussed above and applied in the same manner.

Murdock does not disclose the use of sensors.

Page 5

Haak discloses an iontophoretic delivery device comprising a selectively permeable membrane positioned between the agent reservoirs and electrode (abstract).

A control circuit is optionally provided. It may take the form of an on-off switch for on demand drug delivery, a timer, a fixed or variable electrical resistor and a controller which automatically turn the device on and off at some desired periodicity to match the natural or circadian patterns of the body (column 10, lines 57-60). The control circuit may include an integrated circuit which could be designed to control the dosage of beneficial agent, or to respond to sensor signals in order to regulate the dosage to maintain a predetermined dosage regimen (column 11, lines 3-7).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have incorporated the circuit control of Haak into the device of Murdock in order to control the dosage of the beneficial agent and to regulate the dosage to maintain a predetermined dosage as described by Haak.

Application/Control Number: 10/711,389 Page 6

Art Unit: 1615

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA S. MERCIER whose telephone number is (571)272-9039. The examiner can normally be reached on 8:00am-4:30pm Mon through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Melissa S Mercier/ Examiner, Art Unit 1615 /MP WOODWARD/ Supervisory Patent Examiner, Art Unit 1615